Centre National De La Recherche Scientifique

Other

Pierre Jean-Paul Potier

Robert H Dodd

Alain Valla

Dominique Cartier

Roger Labia

Martial Ruat

Albane Kessler

Philippe Marcel Dauban

Claude Thal

Joanna Bakala

Maria Conception Achab

Erwin Sigel

Roman Furtmuller

Urs Thomet

Frantisek Jursky

Werner Sieghart

Gisèle Franck

Nobumichi-André Sasaki

Hélène Véronique Faure

Yves Fromes

Nathalie Cheviron

Rodolphe Razet

Nobumichi-Andre Sasaki

Maria Conception I/achib

Francoise Lawrence

The invention concerns compounds of formula (1) wherein in particular G represents the &#x2014;N(CH)&#x2014;, &#x2014;N(CH)-group or N-pyrrolidine: n is an integer equal to 1 or 2: R, Rand R, independently of one another, represent a hydrogen atom or a methyl group, the successive unsaturated units capable of being moreover identical or different, provided that at least one of the substituents R, Rand Ris different from H: and Yand Yrepresent each a &#x2014;COOCHgroup or a COOCHgroup.

Intermediates for use in retinoid synthesis

The present invention relates to the use of biguanide derivatives of general formula I below: in which:

Use of biguanide derivatives for making a medicine having a wound healing effect

The invention concerns diamines of general formula (I), wherein: A represents a group A1 or A2 of general formula (II); B represents a group B1 or B2 of general formula (III); X represents a SO, CH, C&#x2550;O or COO; YZ represents a group of formula CH(R25)&#x2014;CH(R26) or CH(R27)&#x2550;(R28), and R1 to R28, identical or different, represent independently of one another, a hydrogen or halogen atom or an alkyl, cycloalkyl, CN, NO, hydroxy, aryl, aralkyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, arylalkylamino, diarylamino diarylalkylamino, trihalogenoalkyl or trihalogenoalkoxy group, provided that in the group A1, at least one of the radicals R1, R2, R3, R4 or R5 represents the hydrogen atom when the other four do not represent the hydrogen atom and in the group B1, at least one of the radicals R13, R14, R15, R16 or R17 represents the hydrogen atom when the other four do not represent the hydrogen atom, and their salts with a pharmaceutically acceptable acid, in the form of racemic mixture or their optically pore isomers. The invention also concerns their preparation, pharmaceutical compositions comprising them and their use as CaSR activity modulator and as medicine particularly designed for the treatment of psychological diseases and disorders involving CaSR activity modulation.

Diamines having a CaSR modulating activity

The invention concerns compounds of formula (1) wherein in particular G represents the &#x2014;N(CH)&#x2014;, &#x2014;N(CH)-group or N-pyrrolidine: n is an integer equal to 1 or 2: R, Rand R, independently of one another, represent a hydrogen atom or a methyl group, the successive unsaturated units capable of being moreover identical or different, provided that at least one of the substituents R, Rand Ris different from H: and Yand Yrepresent each a &#x2014;COOCHgroup or a &#x2014;COOCHgroup.

The invention concerns compounds of general formula (I) wherein: the group X represents a &#x2014;NR4, &#x2014;CH&#x2550;N or &#x2014;CHR5-NR4-group; the group Y represents an oxygen or sulphur atom or a NR, &#x2014;CR5, &#x2014;CHR5-, &#x2014;CR5=CR6- or &#x2014;CHR5-CHR6 group provided that when group X represents the &#x2014;CH&#x2550;N&#x2014; or &#x2014;CHR5-NR4-group, group Y represents an oxygen or a sulphur atom or a Nr, &#x2014;CR5 or &#x2014;CHR group; the group R represents a hydrogen atom or an alkyl, aryl or aralkyl group; the groups R1, R5 and R6, identical or different, represent each a hydrogen or halogen atom or an alkyl or alkoxy group; the group R2 represents a hydrogen atom or an alkyl group; the group R3 represents an aryl group; and the group R4 represents a hydrogen atom, an alkyl, aryl, aralkyl, alkylsulphonamide, arylsulphonamide or aralkylsulphonamide group; and their salt with a pharmaceutically acceptable acid, in the form of a racemic mixture and their optically pure isomer. The invention also concerns their preparation, pharmaceutical compositions containing them and their use as CaSR activity modulator and as medicine for preferably treating diseases or physiological disorders involving the intervention of CaSR activity modulation. 

Calcium receptor active molecules and method for preparing same

The invention concerns compounds of formula (1) wherein in particular G represents the &#x2014;N(CH)&#x2014;, &#x2014;N(CH)&#x2014; group or N-pyrrolidine: n is an integer equal to 1 or 2: R, Rand R, independently of one another, represent a hydrogen atom or a methyl group, the successive unsaturated units capable of being moreover identical or different, provided that at least one of the substituents R, Rand Ris different from H; and Yand Yrepresent each a &#x2014;COOCHgroup or a &#x2014;COOCHgroup.

The invention concerns compounds of general formula (I) wherein: Z represents a sulphur or oxygen atom, NH, N-alkyl or Nboc; group R&prime;, identical or different, represent each a hydrogen atom, a OCH group or a OCH O group; group R&Prime; represents a hydrogen or a CH group; group X represents a carbonyl, sulphonyl or CO group; and group R represents an alkyl, aryl, alkenyl or aralkyl group. The invention also concerns the preparation of said compounds, pharmaceutical compositions containing them and their use for stimulating &ggr;-amino-butyric acid activity and as medicine for treating nervous disorders.

N-substituted 1-(lactone) isoquinolones for treating nervous disorders

Growing community of inventors

Paris, France

Pierre Jean-Paul Potier